ArticleBiomaterials2012
Using breast cancer cell CXCR4 surface expression to predict liposome binding and cytotoxicity.
Article in Biomaterials, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 45 citations in OpenAlex.
- CXC chemokine receptor 4 (CXCR4) targeted gold nanoparticles potently enhance radiotherapy outcomes in breast cancer.Nanoscale · 2021Article
- A facile magnetic extrusion method for preparing endosome-derived vesicles for cancer drug delivery.Advanced functional materials · 2021Article
- Advanced fluorescence microscopy reveals disruption of dynamic CXCR4 dimerization by subpocket-specific inverse agonists.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- ITGA2 as a potential nanotherapeutic target for glioblastoma.Scientific reports · 2019Article
- Dual complementary liposomes inhibit triple-negative breast tumor progression and metastasis.Science advances · 2019Article
- Advances in Receptor-Mediated, Tumor-Targeted Drug Delivery.Advanced therapeutics · 2019Article
- Peptide density targets and impedes triple negative breast cancer metastasis.Nature communications · 2018Article
- Nanoparticle elasticity directs tumor uptake.Nature communications · 2018Article
- A quantitative method for screening and identifying molecular targets for nanomedicine.Journal of controlled release : official journal of the Controlled Release Society · 2017Article
- Incorporating gold nanoclusters and target-directed liposomes as a synergistic amplified colorimetric sensor for HER2-positive breast cancer cell detection.Theranostics · 2017Article
- Potential of CXCR4/CXCL12 Chemokine Axis in Cancer Drug Delivery.Current pharmacology reports · 2016Article
- Selecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane Proteins.Biomarkers in cancer · 2016Review
- ICAM-1-Targeted, Lcn2 siRNA-Encapsulating Liposomes are Potent Anti-angiogenic Agents for Triple Negative Breast Cancer.Theranostics · 2016Article
- Liposomes coated with N-trimethyl chitosan to improve the absorption of harmine in vivo and in vitro.International journal of nanomedicine · 2016Article
- Use of Targeted Liposome-based Chemotherapeutics to Treat Breast Cancer.Breast cancer : basic and clinical research · 2015Review
- ICAM-1 as a molecular target for triple negative breast cancer.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Inhibiting metastatic breast cancer cell migration via the synergy of targeted, pH-triggered siRNA delivery and chemokine axis blockade.Molecular pharmaceutics · 2014Article
- Albumin-fatty acid interactions at monolayer interface.Nanoscale research letters · 2014Article
- Overexpression of CXCR4 is significantly associated with cisplatin-based chemotherapy resistance and can be a prognostic factor in epithelial ovarian cancer.BMB reports · 2014Article
- An engineered bivalent neuregulin protects against doxorubicin-induced cardiotoxicity with reduced proneoplastic potential.Circulation · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
The primary cause of mortality in breast cancer is tumor aggressiveness, characterized by metastases to regional lymph nodes, bone marrow, lung, and liver. C-X-C chemokine receptor type 4 (CXCR4) has been shown to mobilize breast cancer cells along chemokine gradients. Quantification of CXCR4 surface expression may predict the efficacy of anti-CXCR4 labeled liposomal therapeutics to target and kill breast cancer cells. We evaluated gene and surface receptor expression of CXCR4 on breast cancer cell lines distinguished as having low and high invasiveness, MDA-MB-175VII and HCC1500, respectively. CXCR4 surface expression did not correlate with invasiveness. MDA-MB-175VII exhibited more binding to anti-CXCR4 labeled liposomes relative to HCC1500. Increased binding correlated with greater cell death relative to IgG labeled liposomes. Quantitative cell characterization may be used to select targeted therapeutics with enhanced efficacy and minimal side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.